BCLI
Brainstorm Cell Therapeutics Inc.
Set alert
0.86 USD -0.05 -5.35%
0.856 Day range 0.943
0.48 52-week range 1.44
- YTD
- +56.38%
- 1 year
- +32.32%
- Open
- 0.8703
- Prev close
- 0.90875
- Mkt cap
- 9.49M
- Vol
- 3.48K
- Avg vol
- 23.42K
- EPS
- -0.93
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.856
- High
- 0.943
- Forward P/E
- -0.91
- Beta
- 0.39
- Short ratio
- 1.25
- Inst. own
- 13.90%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.70
- 200-d avg
- 4.88
- 1y target
- 23.45
Key statistics
- Market cap
- 12.72M
- Enterprise value
- 3.92M
- Trailing P/E
- 0.00
- Forward P/E
- -0.91
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -3.45
- Beta
- 0.39
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -8.45M
- Total cash
- 3.47M
- Total debt
- 962.00K
- Return on equity
- 0.00%
- Shares outstanding
- 5.70M
- Short % of float
- 2.19%
- 50-day average
- 1.70
- 200-day average
- 4.88
Analyst view
Consensus: buy
Buy
Price target (mean) 23.45 +2626.4% upside
Now 0.8601
- Target (low)
- 10.00
- Target (mean)
- 23.45
- Target (high)
- 36.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.27.
Financials — quick view
BCLI Revenue — quarterly 0
BCLI Net income — quarterly -2.86M
BCLI EPS — quarterly -0.45
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.45 | -1.80 | -1.35 | -300.00% |
| Aug 14, 2024 | Jun 1, 2024 | -0.60 | -0.60 | 0.00 | 0.00% |
| May 14, 2024 | Mar 1, 2024 | -1.05 | -0.75 | +0.30 | +28.57% |
| Apr 1, 2024 | Dec 1, 2023 | -2.25 | -1.65 | +0.60 | +26.67% |
| Nov 14, 2023 | Sep 1, 2023 | -2.10 | -2.10 | 0.00 | 0.00% |
| Aug 14, 2023 | Jun 1, 2023 | -2.25 | -1.95 | +0.30 | +13.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 11, 2024 | Maxim Group | up | Hold | Buy |
| Sep 28, 2023 | Maxim Group | down | Buy | Hold |
| Mar 31, 2023 | Maxim Group | main | — | Buy |
| Feb 5, 2021 | Maxim Group | up | Hold | Buy |
| May 15, 2018 | HC Wainwright & Co. | init | — | Buy |
| Aug 17, 2017 | Maxim Group | main | — | Buy |
About Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- brainstorm-cell.com
News
- BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions
- BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
- BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
- BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine
- BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors
- BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market
- BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
- Comparing Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Zealand Pharma A/S (OTCMKTS:ZLDPF)
- Brainstorm Cell Therapeutics (NASDAQ:BCLI) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened
- BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update
Your note
Sign in to keep a note on BCLI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DAGHER IBRAHIM B. | Officer | Sale | Jul 18, 2024 | 190,000 |
| HARTOUNIAN HARTOUN | Chief Operating Officer | Stock Award(Grant) | Jun 23, 2024 | 30,000 |
| LEBOVITS CHAIM | Chief Executive Officer | Purchase | May 27, 2024 | 3,165,710 |
| LINDBORG STACY R. PH.D. | Chief Executive Officer | Stock Award(Grant) | Mar 10, 2024 | 423,435 |
| NAOR NIR | Director | Stock Award(Grant) | Jun 18, 2023 | 11,999 |
| PATLIS ALLA | Chief Financial Officer | Stock Award(Grant) | Mar 10, 2024 | 65,246 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 8.06% | 459,846 | 1.03M | Sep 29, 2024 |
| Abner Herrman & Brock Llc | 2.55% | 145,500 | 324.46K | Sep 29, 2024 |
| Vanguard Group Inc | 1.77% | 100,710 | 224.58K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.80% | 45,522 | 101.51K | Sep 29, 2024 |
| Blackrock Inc. | 0.44% | 25,174 | 56.14K | Sep 29, 2024 |
| Liberty Wealth Management LLC | 0.40% | 22,677 | 50.57K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.24% | 70,735 | 157.74K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.50% | 28,431 | 63.40K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.47% | 26,734 | 59.62K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.17% | 9,564 | 21.33K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.12% | 7,079 | 15.79K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.06% | 3,248 | 7.24K | Oct 30, 2024 |